Abstracts tagged "ANCA"

Abstract Number: 0726 • ACR Convergence 2024
Management of ANCA Vasculitis-Associated Orbital Inflammatory Disease: A Systematic Literature Review
Emma Neary¹, Katie Healey², Marie Clements-Baker³, Jean-Paul Makhzoum⁴ and Arielle Mendel⁵, ¹McGill University, Montreal, QC, Canada, ²Memorial University of Newfoundland, St. John's, NL, Canada, ³Queen's University, Kingston, ON, Canada, ⁴Vasculitis Clinic, Canadian Network for Research on Vasculitides, Hopital du Sacre-Coeur de Montreal, Montreal, QC, Canada, ⁵McGill University Health Centre, Montreal, QC, Canada
Background/Purpose: Ocular manifestations are common in ANCA-associated vasculitides (AAV), with orbital inflammatory disease (OID) representing a significant subset. Despite being a vision-threatening complication, OID remains…
Abstract Number: 2494 • ACR Convergence 2024
Clinical Characteristics, Predictors for Mortality and Comparison of the Birmingham Vasculitis Activity Score and the Five-Factor Score on Survival in ANCA-associated Vasculitis in Hong Kong : A Multi-centre Retrospective Cohort Study
Ka Ho Yeung and Kit Yu Young, Caritas Medical Centre, Hong Kong, Hong Kong
Background/Purpose: To describe the clinical profile and predictors of mortality of AAV patients in Hong Kong. To compare the accuracy of the latest Five-factor Score…
Abstract Number: 0727 • ACR Convergence 2024
Prospective Cellular Biomarkers in ANCA Associated Vasculitis: A Pilot Study
Jakub Videman¹, Adela Skoumalova¹, Marketa Dudkova¹, Martina Skacelova¹, Anna Petrackova², Zuzana Mikulkova², Eva Kriegova³ and Pavel Horak¹, ¹3rd Department of Internal Medicine - Nephrology, Rheumatology and Endocrinology, University Hospital Olomouc & Palacky University Olomouc, Faculty of Medicine and Dentistry, Olomouc, Olomoucky kraj, Czech Republic, ²Department of Immunology, Faculty of Medicine and Dentistry, Palacky University and University Hospital, Olomouc, Czechia, Olomouc, Olomoucky kraj, Czech Republic, ³Department of Immunology, Faculty of Medicine and Dentistry, Palacky University and University Hospital, Olomouc, Czechia, Olomouc, Czech Republic
Background/Purpose: Significant progress has been achieved over the course of recent time in elucidating the complex underlying pathophysiological mechanisms of ANCA associated vasculitis (AAV). Despite…
Abstract Number: 2495 • ACR Convergence 2024
Diffuse Alveolar Hemorrhage in Patient with ANCA-associated Vasculitis AndInterstitial Lung Disease
Elif Ediboglu¹, Samuel Falde¹, Misbah Baqir¹, Rodrigo Cartin-Ceba² and Ulrich Specks¹, ¹Mayo Clinic, Rochester, MN, ²Mayo Clinic, Scottsdale, AZ
Background/Purpose: The association of interstitial lung disease (ILD) and microscopic polyangiitis (MPA) is increasingly recognized. The implications of ILD as it relates to clinical outcomes…
Abstract Number: 0728 • ACR Convergence 2024
Glomerular Proteomic Signature in ANCA-associated Glomerulonephritis
Ivana Stojkic¹, Arnon Arazi², Huijuan Song³, Pearlly Yan⁴, Estela Puchulu-Campanella⁴, Hubao Wang³, Lynn Fussner³, Brad Rovin³, Samir Parikh⁵ and Salem Almaani⁶, ¹Nationwide, Columbus, OH, ²Feinstein Institutes for Medical Research, Melrose, MA, ³The Ohio State University, Columbus, OH, ⁴The Ohio State University, Columbus, ⁵Ohio State University, Columbus, OH, ⁶The Ohio State University Medical Center, Columbus, OH
Background/Purpose: Crescentic glomerulonephritis (AAGN) is a common manifestation of ANCA-associated vasculitis (AAV) but does not occur in all patients. It is unclear whether the immune…
Abstract Number: 2496 • ACR Convergence 2024
Clinical Features and Outcomes of Hydralazine-associated Vasculitis: A Case-Control Study
Elif Ediboglu¹, Samuel Falde¹, Misbah Baqir¹, Rodrigo Cartin-Ceba² and Ulrich Specks¹, ¹Mayo Clinic, Rochester, MN, ²Mayo Clinic, Scottsdale, AZ
Background/Purpose: We aimed to investigate the relationship between hydralazine and any form of vasculitis (small, medium, or large vessel), to describe clinical features and outcomes…
Abstract Number: 0729 • ACR Convergence 2024
Factors Associated with Pauci-immune Glomerulonephritis in Patients Undergoing Renal Biopsy with Positive ANCA Results
Jiyun Lee¹, Yeo-Jin Lee², Mi-Ra Cho³, Young-Eun Kim⁴, Soo Min Ahn⁴, Ji Seon Oh³, Yong-Gil Kim³, Chang-Keun Lee³, Bin Yoo³ and Seokchan Hong³, ¹University of Ulsan College of Medicine, Seoul, Republic of Korea, ²Asan medical center, Seoul, South Korea, ³Asan Medical Center, Seoul, Republic of Korea, ⁴Asan medical center, University of Ulsan College of Medicine, Seoul, Republic of Korea
Background/Purpose: Pauci-immune glomerulonephritis (GN) is a renal manifestation of anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV). When patients present with positive ANCA results and urinary abnormalities…
Abstract Number: 2512 • ACR Convergence 2024
French Multicenter Retrospective Study of Patients with Cocaine- and/or Levamisole-induced Vasculitis and Vasculopathy
Kevin Chevalier¹, François Chasset², Yoann Zerbib³, Pierre-André Jarrot⁴, Romain Muller⁴, Thomas Pires⁵, Saroumadi Adavane⁶, Didier Bessis⁷, Alban Deroux⁸, Vincent Descamps⁹, Fanny Domont¹⁰, Joëlle Faddoul¹⁰, Pierre-Edouard gavand¹¹, Tiphaine Goulenok¹², Baptiste Gramont¹³, Vincent Jachiet¹⁴, Gaëlle Leroux¹⁵, Matthieu Mahevas¹⁶, Julie Merindol¹⁷, Loïc Meudec¹⁸, Martin Michaud¹⁹, Morgane Mourguet²⁰, Héloïse Munos pons²¹, Yann Nguyen²², Bénédicte Oules²³, Thomas Papo²⁴, Jacques Pouchot²⁵, Sébastien Rivière¹⁴, Oscar Robert²⁶, Charles ronsin²⁷, Benjamin Rossi²⁸, Delphine Staumont-salle²⁹, Benjamin Terrier³⁰, Nathalie Tieule³¹, Vollmer Olivier³², Pierre Wolkenstein³³, Xavier Puéchal³⁴, Jean-David Bouaziz³⁵, Nicolas Dupin²³, Gilles Peytavin³⁶, Jean-Claude Alvarez³⁷, Luc Mouthon³⁸ and Alexis Régent³⁴, ¹Department of Internal Medicine, National Reference Center for Rare Systemic Autoimmune Diseases, Hôpital Cochin, Assistance Publique-Hôpitaux de Paris, Université Paris Cité, Paris, France, Paris, France, ²Dermatology, Hôpital Tenon, Paris, France, ³Medical Intensive Care Unit and MP3CV-EA7517, Amiens University Hospital, Amiens, France, Amiens, France, ⁴Service de Médecine Interne et Immunologie Clinique, Hôpital de La Conception, Marseille, Marseille, France, ⁵Department of Internal Medicine, CHU Bordeaux, Bordeaux, France., Bordeaux, France, ⁶Service de Cardiologie, Hôpitaux Saint-Antoine and Tenon, AP-HP, 75012 Paris, France., Paris, France, ⁷Department of Dermatology and Reference Center for Rare Skin Diseases (MAGEC), Saint-Eloi Hospital, University of Montpellier and INSERM U1058, Montpellier, France., Montpellier, France, ⁸Clinique Universitaire de Médecine Interne, Department of Internal Medicine, Grenoble University Hospital, Grenoble, France, ⁹Department of Dermatology, APHP, Bichat Hospital, Paris, France., Paris, France, ¹⁰AP-HP. Centre de Référence des Maladies Auto-Immunes Systémiques Rares, Centre de Référence des Maladies Auto-Inflammatoires et de l'Amylose Inflammatoire, F-75013 Paris, France., Paris, France, ¹¹Department of Internal Medicine, Clinique Rhena, Strasbourg, France., Strasbourg, France, ¹²Assistance Publique Hôpitaux de Paris, Paris, France, ¹³Internal Medicine Departement, Saint Etienne, Saint Etienne, France, ¹⁴Service de médecine interne, AP-HP, Hôpital Saint Antoine, Sorbonne Universite, Paris, France., Paris, France, ¹⁵Service de Médecine Interne, AP-HP Hôpital Pitié-Salpêtrière, Paris, France., Paris, France, ¹⁶Department of Internal Medicine, APHP, Mondor Hospital, Paris, France., Créteil, France, ¹⁷Internal Medicine Department, University Hospital of Nice, Côte d'Azur University, Nice, Provence-Alpes-Côte d'Azur, France., Nice, France, ¹⁸Department of Rheumatology, Université Paris-Saclay, Hôpital Bicêtre, Assistance Publique-Hôpitaux de Paris, Le Kremlin Bicêtre, France., Kremlin Bicêtre, France, ¹⁹Department of Internal Medicine, Clinique Saint-Exupery, Toulouse, France., Toulouse, France, ²⁰service de médecine interne CHU Toulouse RANGUEIL, Toulouse, France, ²¹Department of Internal Medicine, Saint-Etienne University Hospital, Saint-Etienne, France., Saint Etienne, France, ²²Université Paris Saclay, Clichy, Ile-de-France, France, ²³Dermatology Department, Cochin Hospital, Paris, France., Paris, France, ²⁴Université Paris Cité, Paris, France, ²⁵Service de médecine Interne, Centre National de Référence des syndromes drépanocytaires majeurs de l'adulte, AP-HP, Hôpital Européen Georges Pompidou, Paris, France, Paris, France, ²⁶Groupe Hospitalier Pitié Salpêtrière, Assistance Publique Hopitaux de Paris, Service de Pneumologie et Réanimation Médicale, Paris, France; [email protected]., Paris, France, ²⁷cHD Vendée, La Roche sur Yon, La Roche sur Yon, France, ²⁸Service de médecine interne, maladies infectieuses, Centre hospitalier intercommunal de Robert Ballenger, Aulnay-sous-bois, France., Aulnay-sous-bois, France, ²⁹Service de dermatologie, CHU de Lille, université de Lille, 59000 Lille, France., Lille, France, ³⁰Service de Médecine interne, Hôpital Cochin, AP-HP, Paris, Ile-de-France, France, ³¹Rhumatologie, Centre Hospitalier Universitaire Nice, Hôpital Pasteur, Nice, France, ³²Department of Immunology and Internal Medicine, Strasbourg University Hospital, Strasbourg, France., Strasbourg, France, ³³Department of Dermatology, National Referral Center for Neurofibromatosis, Henri Mondor University Hospital, Assistance Publique- Hôpitaux de Paris, Creteil, France., Créteil, France, ³⁴National Referral Center For Rare Systemic Autoimmune Diseases, Paris, France, ³⁵Dermatology, Hopital Saint-Louis, Paris, Île-de-France, France., Paris, France, ³⁶Service de Pharmacologie, Université Paris Cité, INSERM, IAME, UMR 1137, AP-HP, Hôpital Bichat-Claude Bernard, Paris, France., Paris, France, ³⁷Service de Pharmacologie‑Toxicologie, Hôpital Raymond Poincaré, Groupe Hospitalier Universitaires AP-HP.Paris-Saclay, Garches, 92380, France, Paris, France, ³⁸Service de Médecine Interne, Centre de Référence Maladies Systémiques Autoimmunes et Autoinflammatoires Rares d'Ile de France de l’Est et de l’Ouest, Hôpital Cochin, Assistance Publique-Hôpitaux de Paris (AP-HP), Paris, France
Background/Purpose: Levamisole, an imidazothiazole formerly used as an anthelmintic, is also used as a cutting agent to enhance the effects and duration of cocaine. In…
Abstract Number: 0731 • ACR Convergence 2024
Differentiating Primary Anti-Neutrophil Cytoplasmic Antibody (ANCA) Associated Vasculitis from Secondary Forms
Adil Vural¹, Kinanah Yaseen², Cassandra Calabrese³ and Adam Brown⁴, ¹Cleveland Clinic, Avon, OH, ²Cleveland Clinic, Cleveland, OH, ³Cleveland Clinic Foundation, Cleveland Heights, OH, ⁴Cleveland Clinic Foundation, Cleveland, OH
Background/Purpose: ANCA associated vasculitis (AAV) is a severe autoimmune disorder with substantial morbidity and mortality. Establishing the diagnosis might be challenging due to the existence…
Abstract Number: 2690 • ACR Convergence 2024
ANCA IgG Promotion of Neutrophil Recruitment, Migration and Vascular Damage in ANCA Associated Vasculitis May Be Enhanced by Hypoxia
Noelle Pisacano, Amrita Dhutia, Stephen Rothery, Charles Pusey, Edwin Chilvers, Andrew Cowburn, Katharine Lodge and Maria Prendecki, Imperial College London, London, United Kingdom
Background/Purpose: Neutrophils are main mediators of disease in ANCA associated vasculitis (AAV). Pathogenic ANCA IgG on neutrophils promotes neutrophil adhesion and migration at the endothelium.…
Abstract Number: 0734 • ACR Convergence 2024
Insights into Readmissions of ANCA-Vasculitis Patients: A Nationwide Analysis
Faria Sami¹ and Rohan Gajjar², ¹University of Alabama, Chicago, IL, ²John H. Stroger Hospital of Cook County, Chicago, IL
Background/Purpose: ANCA vasculitis is an immune-medicated inflammation affecting small-medium vessels and manifesting with a wide spectrum of clinical manifestations most commonly involving the lungs and…
Abstract Number: 2692 • ACR Convergence 2024
Transcriptomic Profiling of Kidney Biopsies Implicates Th17 and IL-17 in ANCA-Associated Vasculitis
Ivana Stojkic¹, Arnon Arazi², Huijuan Song³, Pearlly Yan⁴, Estela Puchulu-Campanella³, Hubao Wang³, Lynn Fussner³, Brad Rovin³, Samir Parikh⁵, Stacy Ardoin⁶, Daniel Koboldt⁷, James Fitch⁷ and Salem Almaani⁸, ¹Nationwide, Columbus, OH, ²Feinstein Institutes for Medical Research, Melrose, MA, ³The Ohio State University, Columbus, OH, ⁴The Ohio State University, Columbus, ⁵Ohio State University, Columbus, OH, ⁶Nationwide Children's Hospital, Columbus, OH, ⁷Steve and Cindy Rasmussen Institute for Genomic Medicine, Columbus, OH, ⁸The Ohio State University Medical Center, Columbus, OH
Background/Purpose: ANCA-associated vasculitis (AAV) is a severe autoimmune disease targeting small vessels, with significant kidney involvement. Despite current therapies, up to 28% of patients progress…
Abstract Number: 0774 • ACR Convergence 2024
A Multicenter, Randomized, Controlled Trial to Evaluate the Effects of Low-dose Glucocorticoids Compared to Stopping Glucocorticoids to Maintain Remission of Granulomatosis with Polyangiitis: The TAPIR Trial
Peter Merkel¹, Christian Pagnoux², Nader Khalidi³, Ulrich Specks⁴, Curry Koening⁵, Carol Langford⁶, Larry Moreland⁷, Paul Monach⁸, Jason Springer⁹, Shubhasree Banerjee¹, Simon Carette¹⁰, Rennie Rhee¹, Medha Soowamber¹¹, Kenneth Warrington⁴, Renee Borchin¹², Cristina Burroughs¹³, Carol McAlear¹, David Cuthbertson¹³ and Jeffrey Krischer¹³, ¹University of Pennsylvania, Philadelphia, PA, ²Mount Sinai Hospital, Toronto, ON, Canada, ³McMaster University, Hamilton, ON, Canada, ⁴Mayo Clinic, Rochester, MN, ⁵University of Texas Dell Medical School, Austin, TX, ⁶Cleveland Clinic, Moreland Hills, OH, ⁷University of Colorado, Denver, CO, ⁸VA Boston Healthcare System, Boston, MA, ⁹Vanderbilt University Medical Center, Franklin, TN, ¹⁰Mount Sinai Hosptial, Toronto, ON, Canada, ¹¹University of Toronto, Toronto, ON, Canada, ¹²University of South Florida, Tampa, ¹³University of South Florida, Tampa, FL
Background/Purpose: Use of low-dose glucocorticoids to maintain remission in patients with granulomatosis with polyangiitis (GPA) remains controversial. Additionally, there is no consensus on how to…
Abstract Number: 2693 • ACR Convergence 2024
Risk Factors for Relapse in ANCA-Associated Vasculitis Among Patients with Relapse After Induction of Remission with Rituximab
Ellen Romich¹, Joshua Baker², Ian Green², Rennie Rhee², Carol McAlear², Ulrich Specks³, Rona Smith⁴, David Jayne⁴ and Peter Merkel², and the RITAZAREM Investigators, ¹University of Pennsylvania, Media, PA, ²University of Pennsylvania, Philadelphia, PA, ³Mayo Clinic, Rochester, MN, ⁴University of Cambridge, Cambridge, United Kingdom
Background/Purpose: Relapses are common in ANCA-associated vasculitis (AAV), both i) during maintenance treatment after induction of remission, and ii) after immunosuppressive treatment is discontinued. Relapses…
Abstract Number: 2381 • ACR Convergence 2023
ANCA-associated Vasculitis and Renal Disease in a Multidisciplinary Outpatient Clinic in Northern Spain
Salma Al Fazazi¹, Fabricio Benavides², Vanesa Calvo Río³, maria rodriguez Vidriales², clara escagedo Cagigas², monica renuncio garcia², luis martin penagos⁴ and Ricardo Blanco⁵, ¹Hospital Universitario Puerta Del Mar, Cádiz, Spain, ²Hospital Universitario Marqués de Valdecilla, Santander, Spain, ³Valdecilla Hospital, Santander, Spain, ⁴Division of Nephrology, Immunopathology Group, Hospital Universitario Marqués de Valdecilla-DIVAL, Santander, Spain, ⁵Hospital Universitario Marqués de Valdecilla, IDIVAL, Santander, Spain
Background/Purpose: The severity of clinical features and outcomes in previous series of patients reported with renal disease related to ANCA-associated vasculitis (AAV) vary greatly, probably…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].